Credit Ratings Affirmed: AM Best has affirmed the Financial Strength Rating of A+ and Long-Term Issuer Credit Ratings of "aa" for Aflac Life Insurance Japan and its subsidiaries, indicating strong financial stability and performance.
Strong Financial Metrics: Aflac's risk-adjusted capitalization is at the strongest level, with robust operating margins, improving return-on-revenue and return-on-equity metrics, and a stable outlook for its credit ratings.
AFL
$111.5+Infinity%1D
Analyst Views on AFL
Wall Street analysts forecast AFL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AFL is 112.80 USD with a low forecast of 101.00 USD and a high forecast of 127.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
Wall Street analysts forecast AFL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AFL is 112.80 USD with a low forecast of 101.00 USD and a high forecast of 127.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
5 Hold
2 Sell
Hold
Current: 110.050
Low
101.00
Averages
112.80
High
127.00
Current: 110.050
Low
101.00
Averages
112.80
High
127.00
Morgan Stanley
Equal Weight
maintain
$118 -> $120
2025-12-15
New
Reason
Morgan Stanley
Price Target
$118 -> $120
2025-12-15
New
maintain
Equal Weight
Reason
Morgan Stanley raised the firm's price target on Aflac to $120 from $118 and keeps an Equal Weight rating on the shares. Lower interest rates and a steady or better equity market should serve as the broader macro backdrops and 2026 should see "similar fundamental trends as 2025," the analyst tells investors in a life insurance group outlook note.
Mizuho
Underperform
initiated
$104
2025-12-15
New
Reason
Mizuho
Price Target
$104
2025-12-15
New
initiated
Underperform
Reason
Mizuho initiated coverage of Aflac with an Underperform rating and $104 price target. The firm is cautious on the company's sales growth in Japan and the U.S. Aflac's longer term earnings growth will be "capped" by limited sales growth, which is not priced into the shares at current levels, the analyst tells investors in a research note.
Morgan Stanley
Equal Weight
maintain
$113 -> $118
2025-11-17
Reason
Morgan Stanley
Price Target
$113 -> $118
2025-11-17
maintain
Equal Weight
Reason
Morgan Stanley raised the firm's price target on Aflac to $118 from $113 and keeps an Equal Weight rating on the shares. The firm updated models in the insurance space post the Q3 reports. Life insurance earnings reports were better than what share price reactions would suggest, the analyst tells investors in a research note. For property and casualty, Morgan Stanley sees a softening cycle heading into 2026.
Keefe Bruyette
Market Perform
maintain
$110 -> $115
2025-11-11
Reason
Keefe Bruyette
Price Target
$110 -> $115
2025-11-11
maintain
Market Perform
Reason
Keefe Bruyette raised the firm's price target on Aflac to $115 from $110 and keeps a Market Perform rating on the shares.
About AFL
Aflac Incorporated provides financial protection to policyholders and customers through its subsidiaries in the United States and Japan. The Company’s principal business is supplemental health and life insurance products. The Company’s segments include Aflac Japan, which includes Aflac Life Insurance Japan (ALIJ), and Aflac U.S., which includes American Family Life Assurance Company of Columbus (Aflac), American Family Life Assurance Company of New York (Aflac New York), Continental American Insurance Company (CAIC), Tier One Insurance Company (TOIC) and Aflac Benefits Solutions, Inc. (ABS). The Aflac Japan segment is the insurer in Japan in terms of cancer and medical (third sector insurance products) policies in force. The Company designs its United States insurance products to provide supplemental coverage for people who already have major medical or primary insurance coverage, as Aflac U.S. insurance policies pay benefits regardless of other insurance.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
